Marianne  De Backer net worth and biography

Marianne De Backer Biography and Net Worth

Director of Kronos Bio
Dr. De Backer has been a strategist, scientist, business leader, deal maker and corporate investor in the healthcare industry for more than two decades. She has been directly accountable for more than 200 strategic alliances in healthcare, some of which have led to newly approved medicines now available to patients. Dr. De Backer is currently chief business officer and executive vice president, Strategy and Business Development and Licensing, at Bayer AG, and a member of the Executive Committee of Bayer Pharmaceuticals. Before joining Bayer in 2019, she spent more than 20 years at the Johnson & Johnson family of companies. She started as a scientist and scientific group leader, during which time her work resulted in multiple patents. She progressed through commercial positions internationally, including leading a sales and marketing business unit responsible for several therapies, culminating as senior vice president, M&A Operations, Divestitures and Janssen Business Development. She currently serves on the boards of directors of the Gladstone Foundation and Arrowhead Pharmaceuticals. Dr. De Backer holds an M.S. in molecular biology from the Vrije Universiteit Brussels, an M.S. in engineering and biochemistry and a Ph.D. in biotechnology from the University of Ghent, and an MBA from the Rotterdam School of Management at Erasmus University.

What is Marianne De Backer's net worth?

The estimated net worth of Marianne De Backer is at least $649,893.96 as of April 3rd, 2024. Dr. De Backer owns 678,457 shares of Kronos Bio stock worth more than $649,894 as of December 22nd. This net worth approximation does not reflect any other assets that Dr. De Backer may own. Learn More about Marianne De Backer's net worth.

How do I contact Marianne De Backer?

The corporate mailing address for Dr. De Backer and other Kronos Bio executives is , , . Kronos Bio can also be reached via phone at 650-781-5200 and via email at [email protected]. Learn More on Marianne De Backer's contact information.

Has Marianne De Backer been buying or selling shares of Kronos Bio?

Marianne De Backer has not been actively trading shares of Kronos Bio during the last quarter. Most recently, on Wednesday, December 1st, Backer Marianne De bought 1,150 shares of Kronos Bio stock. The stock was acquired at an average cost of $11.57 per share, with a total value of $13,305.50. Learn More on Marianne De Backer's trading history.

Who are Kronos Bio's active insiders?

Kronos Bio's insider roster includes Norbert Bischofberger (CEO), Marianne De Backer (Director), Jorge DiMartino (VP), Christopher Dinsmore (Insider), and Jakob Loven (Director). Learn More on Kronos Bio's active insiders.

Are insiders buying or selling shares of Kronos Bio?

During the last year, Kronos Bio insiders bought shares 3 times. They purchased a total of 2,671,662 shares worth more than $2,787,697.16. During the last year, insiders at the sold shares 4 times. They sold a total of 37,419 shares worth more than $43,196.58. The most recent insider tranaction occured on June, 27th when CEO Norbert W Bischofberger bought 410,848 shares worth more than $480,692.16. Insiders at Kronos Bio own 24.4% of the company. Learn More about insider trades at Kronos Bio.

Information on this page was last updated on 6/27/2024.

Marianne De Backer Insider Trading History at Kronos Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2021Buy1,150$11.57$13,305.50View SEC Filing Icon  
8/20/2021Buy1,000$19.57$19,570.001,100View SEC Filing Icon  
5/28/2021Buy600$25.01$15,006.00600View SEC Filing Icon  
See Full Table

Marianne De Backer Buying and Selling Activity at Kronos Bio

This chart shows Backer Marianne De's buying and selling at Kronos Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kronos Bio Company Overview

Kronos Bio logo
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $0.96
Low: $0.92
High: $0.97

50 Day Range

MA: $0.94
Low: $0.83
High: $1.07

2 Week Range

Now: $0.96
Low: $0.69
High: $1.60

Volume

78,382 shs

Average Volume

278,920 shs

Market Capitalization

$57.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83